
Eyestem completes phase 1 study of Eyecyte-RPE in patients with geographic atrophy
Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE. The company has submitted the results to the Central Drugs Standard Control Organisation (CDSCO), India's …